Literature DB >> 24102940

Epidemiology of Helicobacter pylori in Bhutan: the role of environment and Geographic location.

Dorji Dorji1, Tashi Dendup, Hoda M Malaty, Kinley Wangchuk, Deki Yangzom, James M Richter.   

Abstract

BACKGROUND: Bhutan is small mountainous country bordering India and China and consists of four geographic regions, west, east, central, and south. The epidemiology of Helicobacter pylori infection and risk factors associated with in Bhutan are not previously studied. The World Health Organization reported the incidence of stomach cancer to be very high in Bhutan. AIM: We conducted a cross-sectional study to determine the seroepidemiologic pattern of H. pylori among Bhutanese from the four regions with emphasis on water source and household sanitation.
METHODS: Between June and November 2012, blood samples from patients with complaints of dyspepsia were collected after obtaining an informed consent. Demographic information, occupation, family size living in the same household, consumption of betel nut, and aspects of household environment including type of latrines, source of drinking water were collected. All serum samples were tested for H. pylori immunoglobulin G (IgG) by enzyme-linked immunosorbent assay (ELISA) using MAGIWELL ELISA kit from United Biotech, USA.
RESULTS: Two hundred and forty-four patients between 17 and 75 years of age participated in the study, of them, 102 were men, and the mean age was 38 (±14.2) years. The overall prevalence of H. pylori among patients was 86% with no difference between men and women (90 vs 83%, respectively, p = .12). The prevalence was almost identical among all age groups: 81% at 17-20, 84% at 20-29, 93% at 30-39, 82% at 40-49, 87% at 50-59, and 82% at ≥60 years (p = .51). H. pylori prevalence was lower in the southern region of Bhutan (78%) compared with the central region (97%) (OR = 8.6; 95% CI = 1.1-55; p = .02), eastern region (91%) (OR = 2.7; 95% CI = 1.1-7.2, p = .004) or the western region (83%) (OR = 1.4, 95% CI = 0.8-3.1, p = .07). The prevalence of H. pylori was significantly lower among household with less than 4 persons living in the same household. Source of drinking water, type of occupation, type of latrines, or consumption of betel nut showed no association with H. pylori prevalence. Logistic regression analysis revealed that residing region was the only significant variable.
CONCLUSIONS: The high prevalence of antibodies to H. pylori among patients and in all groups could contribute to the high incident rate of gastric cancer in Bhutan. Crowded living condition and the residing region contribute to the variation of the prevalence of the infection. The lowest prevalence in southern part of the country could be due to the difference in the ethnicity as most of its population is of Indian and Nepal origin. Further data regarding H. pylori in Bhutan are critical to developing surveillance and prevention strategies for gastric cancer.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Bhutan; Helicobacter pylori; epidemiology

Mesh:

Substances:

Year:  2013        PMID: 24102940     DOI: 10.1111/hel.12088

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  9 in total

1.  Geographical distribution of the incidence of gastric cancer in Bhutan.

Authors:  Tashi Dendup; James M Richter; Yoshio Yamaoka; Kinley Wangchuk; Hoda M Malaty
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing?

Authors:  Mustafa Akar; Fuat Aydın; Tuba Kayman; Seçil Abay; Emre Karakaya
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 2.925

3.  Current prevalence of Helicobacter pylori infection in patients with dyspepsia treated in Warsaw, Poland.

Authors:  Tadeusz Tacikowski; Sa'eed Bawa; Danuta Gajewska; Joanna Myszkowska-Ryciak; Jacek Bujko; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2017-05-30

4.  Relationship between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis.

Authors:  Taiwu Wang; Xiang Li; Qi Zhang; Bingjie Ge; Jinhai Zhang; Lei Yu; Tongjian Cai; Yao Zhang; Hongyan Xiong
Journal:  BMJ Open       Date:  2019-06-27       Impact factor: 2.692

5.  Magnitude of Helicobacter pylori among Dyspeptic Patients Attending at University of Gondar Hospital, Gondar, Northwest Ethiopia.

Authors:  Desie Kasew; Ashenafi Abebe; Ufaysa Munea; Tekalign Deressa; Yalewayker Tegegne; Martha Alemayehu; Mulugeta Melku
Journal:  Ethiop J Health Sci       Date:  2017-11

6.  Seroprevalence of Helicobacter pylori in Hispanics living in Puerto Rico: A population-based study.

Authors:  María González-Pons; Marievelisse Soto-Salgado; Javier Sevilla; Juan M Márquez-Lespier; Douglas Morgan; Cynthia M Pérez; Marcia Cruz-Correa
Journal:  Helicobacter       Date:  2017-12-06       Impact factor: 5.753

7.  Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study).

Authors:  Ratha-Korn Vilaichone; Natsuda Aumpan; Thawee Ratanachu-Ek; Pornpen Gamnarai; Tomahisa Uchida; Lotay Tshering; Varocha Mahachai; Yoshio Yamaoka
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01

8.  Clinical and Socio- Demographic Risk Factors for Acquisition of Helicobacter pylori Infection in Nigeria

Authors:  Stella Smith; Tolu Jolaiya; Muinah Fowora; Pia Palamides; Favour Ngoka; Moses Bamidele; Olufunmilayo Lesi; Charles Onyekwere; Rose Ugiagbe; Ifeanyi Agbo; Dennis Ndububa; Olusegun Adekanle; Abimbola Adedeji; Isaac Adeleye; Ute Harrison
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27

9.  A 5-year trend of Helicobacter pylori seroprevalence among dyspeptic patients at Bahir Dar Felege Hiwot Referral Hospital, Northwest Ethiopia.

Authors:  Meseret Workineh; Desalegn Andargie
Journal:  Res Rep Trop Med       Date:  2016-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.